Trial Profile
Efficacy of sofosbuvir/ ledipasvir ± ribavirin in Spanish prison population with chronic hepatitis C infection
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 16 May 2016 New trial record
- 17 Apr 2016 Preliminary results (n=49) presented at The International Liver Congress™ 2016